Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q1 2025 value amounting to $7000.0.

  • Insight Molecular Diagnostics' Amortizatization of Intangibles fell 6818.18% to $7000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $29000.0, marking a year-over-year decrease of 6704.55%. This contributed to the annual value of $88000.0 for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q1 2025, Insight Molecular Diagnostics' Amortizatization of Intangibles is $7000.0, which was down 6818.18% from $22000.0 recorded in Q4 2024.
  • Insight Molecular Diagnostics' 5-year Amortizatization of Intangibles high stood at $1.1 million for Q2 2021, and its period low was $7000.0 during Q1 2025.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $22000.0 (2023), whereas its average is $424470.6.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Amortizatization of Intangibles soared by 478181.82% in 2021 and then crashed by 9774.59% in 2023.
  • Insight Molecular Diagnostics' Amortizatization of Intangibles (Quarter) stood at $990000.0 in 2021, then decreased by 20.0% to $792000.0 in 2022, then plummeted by 97.22% to $22000.0 in 2023, then changed by 0.0% to $22000.0 in 2024, then plummeted by 68.18% to $7000.0 in 2025.
  • Its Amortizatization of Intangibles was $7000.0 in Q1 2025, compared to $22000.0 in Q4 2024 and $22000.0 in Q3 2024.